Search | Clinical Trials Finder

Conditions: Relapsed Pediatric Solid Tumors, Refractory Pediatric Solid Tumors, Rhabdomyosarcoma, Ewing Sarcoma, Osteosarcoma, Neuroblastoma, Wilms Tumor, Hepatic Tumor, Germ Cell Tumor, Desmoid Tumor
Interventions: Magnetic Resonance High Intensity Focused Ultrasound; Device
Lead sponsor: AeRang Kim; Other
Eligibility: Up to 30 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Cincinnati, Ohio

Conditions: Advanced Malignant Solid Neoplasm, Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Primary Central Nervous System Neoplasm, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Wilms Tumor
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Bone Scan, Computed Tomography, Ensartinib, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pharmacological Study, Positron Emission Tomography, Radionuclide Imaging, X-Ray Imaging; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 122
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 95 more

Conditions: Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Neuroblastoma, Solid Tumors
Interventions: Idasanutlin, Venetoclax, Cyclophosphamide, Topotecan, Fludarabine, Cytarabine, Intrathecal Chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 0 Years to 30 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Little Rock, Arkansas • Palo Alto, California • Orlando, Florida + 2 more

Conditions: Central Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia, Refractory Acute Leukemia, Solid Neoplasm
Interventions: Larotrectinib Sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 78
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 67 more

Conditions: Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma
Interventions: cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated, Re-irradiation; Drug · Radiation
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: Up to 25 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 15 more

Conditions: Tumors, Hyperuricemia, Tumor Lysis Syndrome
Interventions: Rasburicase (SR29142); Drug
Lead sponsor: Sanofi; Industry
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: Berkley, California • Denver, Colorado • Jacksonville, Florida + 4 more

Conditions: Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions: Vaccine (autologous dendritic cells), Decitabine and Hiltonol; Biological · Drug
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Louisville, Kentucky

Conditions: Pheochromocytoma, Paraganglioma
Interventions: 131I-MIBG; Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 4 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia, Myelocytic, Acute, Pediatric
Interventions: clofarabine (IV formulation); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: Up to 21 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 18
States / cities: Little Rock, Arkansas • Los Angeles, California • Orange County, California + 14 more

Conditions: Solid Tumor
Interventions: Bevacizumab, Temozolomide, Vincristine, Irinotecan, Cefixime; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 30 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions: Daratumumab, Vincristine, Prednisone, Doxorubicin, Peg-asparaginase, Cyclophosphamide, Cytarabine, 6-mercaptopurine, Methotrexate; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 1 Year to 30 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 26
States / cities: Birmingham, Alabama • Phoenix, Arizona • Oakland, California + 22 more

Conditions: Non-hodgkin Lymphoma
Interventions: Epcoritamab; Drug
Lead sponsor: Genmab; Industry
Eligibility: 1 Year to 25 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 8
States / cities: Palo Alto, California • Miami, Florida • Valhalla, New York + 5 more

Conditions: Refractory Acute Leukemia, Relapsed Acute Leukemia, Undifferentiated Leukemia, Bi-Phenotypic Leukemia
Interventions: Venetoclax, Hyper-CVAD; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: BIIB017 (peginterferon beta-1a), Interferon beta type 1a; Drug
Lead sponsor: Biogen; Industry
Eligibility: 10 Years to 18 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 3
States / cities: La Jolla, California • Chapel Hill, North Carolina • Norfolk, Virginia

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: CTL019; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: Up to 25 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 11
States / cities: Los Angeles, California • Stanford, California • Atlanta, Georgia + 8 more

Conditions: Depression
Interventions: Fluoxetine, Relapse prevention cognitive behavioral therapy (CBT); Drug · Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 8 Years to 17 Years
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Immunocompromised, Bone Marrow Transplant, Cancer
Interventions: Micafungin; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months to 10 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Juvenile Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome
Interventions: Biospecimen Collection; Procedure
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: Up to 22 Years
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 164
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 133 more

Conditions: Hodgkins Lymphoma, Non Hodgkins Lymphoma
Interventions: TAA-specific CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia, B-cell, Lymphoma, B-Cell
Interventions: Blinatumomab, Pembrolizumab; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 40 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Central Nervous System Tumor, Pediatric, Neuroblastoma
Interventions: temozolomide, thalidomide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory
Interventions: Cyclophosphamide, Fludarabine, Mesna, CliniMACS, CD19- specific CAR engineered autologous T-cells (SJCAR19 product); Drug · Device · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Leukemia
Interventions: temozolomide; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 14
States / cities: Stanford, California • Indianapolis, Indiana • Minneapolis, Minnesota + 11 more

Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma, Ewing Sarcoma, Hepatoblastoma, Langerhans Cell Histiocytosis, Malignant Germ Cell Tumor, Malignant Glioma, Osteosarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Central Nervous System Neoplasm, Rhabdoid Tumor, Rhabdomyosarcoma, Soft Tissue Sarcoma, Wilms Tumor
Interventions: Laboratory Biomarker Analysis, Vemurafenib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more

Search by objective public record fields.

MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors

Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse

A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).

Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)